Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome
2004-000848-24Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Talnetant dose-ranging with Placebo (2 arms). Primary endpoint: Adequate relief of IBS pain and discomfort. Started Sep 2004; status: completed.
02
Drugs
talnetant
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2004-000848-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000848-24.